Results 51 to 60 of about 2,746 (190)

Impact of combined oral contraceptives and progestin‐only pills on psychological and sexual well‐being of women with endometriosis: A systematic review

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 5, Page 805-818, May 2026.
Hormonal treatments for endometriosis (combined oral contraceptives/progestin‐only pills) do not show increased psychological or sexual risks compared with placebo. When pain is effectively controlled, these therapies appear well tolerated and may improve overall well‐being.
Noemi Salmeri, Martina Piccini, Francesca Caprara, Edgardo Somigliana, Paola Viganò, Paolo Vercellini   +5 more
wiley   +1 more source

Letrozole versus dienogest in endometrioma recurrent after surgery: a randomized controlled trial [PDF]

, 2022
Background: Letrozole is a third-generation aromatase inhibitor. As there is aberrant aromatase production by endometriotic stromal cells and the growth and regression of endometriosis is estrogen-dependent, the use of letrozole to reduce the size and ...
Halder, Suravi, Amir, Mumtahena, Ishrat, Shakeela, Hossain, M. Rifat Zia, Nasrin, Ivy, Rahman, Farzana   +5 more
core   +1 more source

Ovarian reserve may influence the outcome of bone mineral density in patients with long-term use of dienogest

SAGE Open Medicine, 2021
Objective: Long-term administration of dienogest, which is known to have effect on bone mineral density, is frequently done in patients with endometriosis and adenomyosis, but a few studies focused on the bone mineral density changes after finishing the ...
N Yamamoto, O Wada-Hiraike, M Hirano, T Hirata, M Harada, Y Hirota, K Koga, T Fujii, Y Osuga   +8 more
doaj   +1 more source

Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions

Clinical Pharmacology in Drug Development, Volume 15, Issue 4, April 2026.
Abstract Elagolix is a short‐acting oral gonadotropin‐releasing hormone antagonist utilized for treating endometriosis‐associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use in Indian women remain limited.
Sudershan Kumar, Arshad Khuroo, Reshma Quadros, Shruti Dharmadhikari, Chintan Khandhedia, Gaurav Puppalwar, Amey Mane   +6 more
wiley   +1 more source

Effects of Dienogest on Surgically Induced Endometriosis in Rats after Repeated Oral Administration

, 2011
<i>Background:</i> Dienogest demonstrates efficacy for lesion reduction and pain relief in clinical trials of endometriosis. The current study investigated an intraperitoneal animal model of endometriosis to further characterize the effects ...
O.M. Fischer, U. Kaufmann-Reiche, U. Fuhrmann, C. Moeller   +3 more
core   +1 more source

Dienogest [PDF]

Reactions Weekly, 2021
  +4 more sources

New ways in therapy of abnormal uterine bleedings related to adenomyosis [PDF]

Гинекология, 2015
The purpose of research was a comparison of the effect of a three-phase combined oral contraceptive (COC) containing estradiol valerate and dienogest in dynamic mode and single agent containing dienogest, to reduce menstrual blood loss on the background ...
N N Rukhliada, E I Biriukova, M A Melnikova, D M Gasimova   +3 more
doaj  

Environmental photochemistry of dienogest: phototransformation to estrogenic products and increased environmental persistence via reversible photohydration

, 2017
Potent trienone and dienone steroid hormones undergo a coupled photohydration (in light)-thermal dehydration (in dark) cycle that ultimately increases their environmental persistence.
Wammer, Kristine H.
core   +1 more source

Dienogest versus ethinylestradiol/dienogest in patients with secondary dysmenorrhea due to clinical diagnosis of ovarian endometriosis: a multicentric, prospective, controlled study

, 2017
BACKGROUND Endometriosis is a common gynecological condition, affecting an estimated 10% of reproductive age women. Endometriosis can be a debilitating disease for women who experience painful symptoms such as dysmenorrhea, which may have a ...
Marañés Azulay, Raquel Rebeca
core   +1 more source

Long-term clinical outcomes of dienogest for perimenopausal women with symptomatic adenomyosis

Scientific Reports
We aimed to evaluate the successful long-term use of dienogest for the management of pelvic pain and bleeding control in perimenopausal women with symptomatic adenomyosis using real-world data. All women aged ≥ 40 years with adenomyosis who complained of
Chi-Hau Chen, Yi-Heng Lin, Chia-Yi Lee, Hung Shen, Ya-Ting Hsu, Pei-Chi Wu   +5 more
doaj   +1 more source